From Yahoo Finance: 2025-04-15 13:36:00

Experts note a trend of Big Pharma acquisitions involving Chinese corporations, increasing from 20% to 30% in 2024, according to CNBC. Chinese firms’ efficient development skills and lower prices for medications are attracting attention. Eli Lilly and Company (NYSE:LLY) is highlighted as a leading pharmaceutical stock for long-term growth. The company reported a 32% revenue increase in fiscal 2024, exceeding projections. A partnership with AdvanCell aims to enhance cancer treatment through targeted alpha therapies. Tim Anderson of Bank of America Securities maintains a Buy rating on LLY, with a consensus price target of $736.93, implying a 37.73% increase from current levels.



Read more at Yahoo Finance: Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth?